Form 4: Imunon CSO Granted 15,736 Stock Options

Imunon's Chief Scientific Officer, Khursheed Anwer, was granted 15,736 stock options with an exercise price of $3.95, aligning executive incentives with shareholder value.

Summary

• Khursheed Anwer, Chief Scientific Officer of Imunon, Inc. (IMNN), was granted 15,736 stock options.
• The transaction date for the grant was January 2, 2026.
• Each option has an exercise price of $3.95, which represents the closing price of Imunon, Inc. Common Stock on the grant date.
• The options vest over time: 50% on the grant date (January 2, 2026), 25% on the one-year anniversary (January 2, 2027), and the remaining 25% on the second-year anniversary (January 2, 2028).
• The options expire on January 2, 2036.
• Following this transaction, Khursheed Anwer directly beneficially owns 15,736 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The filing reports a routine executive compensation grant, which is generally a neutral to slightly positive event as it aligns management incentives with shareholder value, but does not provide new operational or financial performance data.

Positives

• The grant of stock options to the Chief Scientific Officer aligns management's financial interests with those of shareholders, incentivizing long-term company performance.
• The exercise price of $3.95 per share is set at the closing price on the grant date, indicating a standard equity compensation practice.

Negatives

• No specific negative aspects are reported in this Form 4 filing, as it details a routine equity compensation grant.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

This Form 4 filing does not contain specific forward-looking statements or guidance regarding the company's future performance, but the option grant incentivizes the Chief Scientific Officer for future success.

Industry Context

The grant of stock options to a Chief Scientific Officer is a common practice in the biotechnology and pharmaceutical industries, where long-term incentives are used to retain key talent and align their interests with the company's strategic goals, particularly in research and development-focused roles.

Comparison to Industry Standards

• The vesting schedule, with a portion vesting immediately and the remainder over two years, is a standard approach for executive equity compensation, similar to practices observed at comparable biotech firms like Moderna or BioNTech for key scientific personnel.
• Setting the exercise price at the closing market price on the grant date is a common and compliant method for issuing stock options, ensuring that the options gain value only if the company's stock price appreciates from that point, aligning with shareholder interests.

Related Party Transactions

• The grant of 15,736 stock options to Khursheed Anwer, the Chief Scientific Officer, constitutes a related party transaction as it involves compensation from the company to an executive officer.

Stakeholder Impact

• Shareholders: The option grant aims to align the Chief Scientific Officer's interests with long-term shareholder value creation, potentially leading to improved company performance.
• Employees: This type of compensation can serve as a benchmark or incentive for other key employees, potentially impacting morale and retention.

Next Steps

• Continued vesting of the remaining stock options on January 2, 2027, and January 2, 2028.
• Potential exercise of vested options by the Chief Scientific Officer before the expiration date of January 2, 2036.

Key Dates

Keywords

Imunon, IMNN, stock options, insider transaction, executive compensation, Form 4, Khursheed Anwer, Chief Scientific Officer, equity grant